Mucosal immunization and adjuvants

Current Topics in Microbiology and Immunology

Volumn 386, Issue , 2015, Pages 371-380

  Hasegawa, Hideki ^a   van Reit, Elly ^a   Kida, Hiroshi ^b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; TOLL LIKE RECEPTOR; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; DRUG DESIGN; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY;

ANIMALIA; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; INFLUENZA VACCINES;

EID: 84921680763     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2014_402     Document Type: Article

References (54)

1. Ainai A, Ichinohe T et al (2010) Zymosan enhances the mucosal adjuvant activity of poly(I: C) in a nasal influenza vaccine. J Med Virol 82(3): 476-484.
2. Ainai A, Tamura S et al (2013) Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccin Immunother 9(9): 1962-1970.
3. Aldridge JR Jr, Moseley CE et al (2009) TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 106(13): 5306-5311.
4. Amorij JP, Hinrichs W et al (2010) Needle-free influenza vaccination. Lancet Infect Dis 10(10): 699-711.
5. Asahi-Ozaki Y, Yoshikawa T et al (2004) Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 74(2): 328-335.
6. Asahi Y, Yoshikawa T et al (2002) Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168(6): 2930-2938.
7. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10(11): 787-796.
8. Bekeredjian-Ding I, Jego G (2009) Toll-like receptors-sentries in the B-cell response. Immunology 128(3): 311-323.
9. Berkowska MA, Driessen GJ et al (2011) Human memory B cells originate from three distinct germinal center-dependent and-independent maturation pathways. Blood 118(8): 2150-2158.
10. Bessa J, Jegerlehner A et al (2009) Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol 183(6): 3788-3799.
11. Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25(30): 5467-5484.
12. Caskey M, Lefebvre F et al (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208(12): 2357-2366.
13. Cerutti A (2008) The regulation of IgA class switching. Nat Rev Immunol 8(6): 421-434.
14. Chen K, Cerutti A (2010) Vaccination strategies to promote mucosal antibody responses. Immunity 33(4): 479-491.
15. Couch RB, Kasel JA (1983) Immunity to influenza in man. Annu Rev Microbiol 37: 529-549.
16. Diebold SS, Kaisho T et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663): 1529-1531.
17. Douagi I, Gujer C et al (2009) Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 182(4): 1991-2001.
18. Greenbaum E, Engelhard D et al (2004) Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine 22(20): 2566-2577.
19. Honjo T, Muramatsu M et al (2004) AID: how does it aid antibody diversity? Immunity 20(6): 659-668.
20. Hoskins TW, Davies JR et al (1976) Influenza at Christ's Hospital: March, 1974. Lancet 1(7951): 105-108.
21. Hoskins TW, Davies JR et al (1979) Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1(8106): 33-35.
22. Ichinohe T, Ainai A et al (2009) PolyI: polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 27(45): 6276-6279.
23. Ichinohe T, Pang IK et al (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 108(13): 5354-5359.
24. Ichinohe T, Tamura S et al (2007) Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 196(9): 1313-1320.
25. Ichinohe T, Watanabe I et al (2005) Synthetic double-stranded RNA poly(I: C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79(5): 2910-2919.
26. Jacobs BL, Langland JO (1996) When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 219(2): 339-349.
27. Koyama S, Aoshi T et al (2010) Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2(25): 25ra24.
28. La Gruta NL, Kedzierska K et al (2007) A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 85(2): 85-92.
29. Lee BO, Rangel-Moreno J et al (2005) CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection. J Immunol 175(9): 5827-5838.
30. Londrigan SL, Turville SG et al (2011) N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN. J Virol 85(6): 2990-3000.
31. Lund JM, Alexopoulou L et al (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101(15): 5598-5603.
32. MacLennan IC, Toellner KM et al (2003) Extrafollicular antibody responses. Immunol Rev 194: 8-18.
33. Macpherson AJ, McCoy KD et al (2008) The immune geography of IgA induction and function. Mucosal Immunol 1(1): 11-22.
34. Massacand JC, Kaiser P et al (2008) Intestinal bacteria condition dendritic cells to promote IgA production. PLoS ONE 3(7): e2588.
35. Matzinger P, Kamala T (2011) Tissue-based class control: the other side of tolerance. Nat Rev Immunol 11(3): 221-230.
36. McKinstry KK, Strutt TM et al (2011) Hallmarks of CD4 T cell immunity against influenza. J Intern Med 269(5): 507-518.
37. Nayak JL, Richards KA et al (2010) Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol 23(2): 169-180.
38. Pang IK, Iwasaki A (2011) Inflammasomes as mediators of immunity against influenza virus. Trends Immunol 32(1): 34-41.
39. Puga I, Cols M et al (2010) Innate signals in mucosal immunoglobulin class switching. J Allergy Clin Immunol 126(5): 889-895, quiz 896-887.
40. Renegar KB, Jackson GD et al (1998) In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J Immunol 160(3): 1219-1223.
41. Renegar KB, Small PA Jr et al (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173(3): 1978-1986.
42. Rothaeusler K, Baumgarth N (2010) B-cell fate decisions following influenza virus infection. Eur J Immunol 40(2): 366-377.
43. Seo SU, Kwon HJ et al (2010) MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol 84(24): 12713-12722.
44. Song W, Vaerman JP et al (1995) Dimeric and tetrameric IgA are transcytosed equally by the polymeric Ig receptor. J Immunol 155(2): 715-721.
45. Stokes CR, Soothill JF et al (1975) Immune exclusion is a function of IgA. Nature 255(5511): 745-746.
46. Takada A, Matsushita S et al (2003) Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21(23): 3212-3218.
47. Tamura S, Funato H et al (1991) Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 21(6): 1337-1344.
48. Taylor HP, Dimmock NJ (1985) Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 161(1): 198-209.
49. Tezuka H, Abe Y et al (2007) Regulation of IgA production by naturally occurring TNF/iNOSproducing dendritic cells. Nature 448(7156): 929-933.
50. Wang BZ, Xu R et al (2010) Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11): e13972.
51. Weiser JN, Bae D et al (2003) Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci U S A 100(7): 4215-4220.
52. Yel L (2010) Selective IgA deficiency. J Clin Immunol 30(1): 10-16.
53. Yoo JK, Galligan CL et al (2010) Identification of a novel antigen-presenting cell population modulating antiinfluenza type 2 immunity. J Exp Med 207(7): 1435-1451.
54. Zaheen A, Martin A (2010) Induction and assessment of class switch recombination in purified murine B cells. J Vis Exp (42), pii: 2130. doi: 10. 3791/2130.